Evidence map›Paper›PMID 37766871›Full record

ArticleFrontiers in oncology2023

VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins

Retheesh S Thankan, Elizabeth Thomas, Puranik Purushottamachar, David J Weber, Vidya P Ramamurthy, Weiliang Huang, Maureen A Kane, Vincent C O Njar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Retheesh S ThankanDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United States.
Elizabeth ThomasDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United States.
Puranik PurushottamacharDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United States.
David J WeberThe Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, United States.
Vidya P RamamurthyIsoprene Pharmaceuticals, Inc., Baltimore, MD, United States.
Weiliang HuangDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States.
Maureen A KaneDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States.
Vincent C O NjarDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United States.
University of Maryland, Baltimore · USUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Funding

Development of Next Generation Galeterone Analogs for Prostate Cancer TherapyR01CA224696 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI NJAR, VINCENT COLLINS OFUKA · 2018 to 2022
$2.6M
NCI NIH HHS R01 CA224696
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) and its recently identified subtype, quadruple negative breast cancer (QNBC), collectively account for approximately 13% of reported breast cancer cases in the United States. These aggressive forms of breast cancer are associated with poor prognoses, limited treatment options, and lower overall survival rates. In previous studies, our research demonstrated that VNLG-152R exhibits inhibitory effects on TNBC cells both

Indexed as

eIF4E signalingMNK1 and MNK2 degraderSynoviolin 1 (SYVN1)triple/quadruple negative breast cancer (TNBC/QNBC)VNLG-152R and deuterated analogs

Identifiers

PMID37766871
PMCPMC10520556
OpenAlexW4386607549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.